GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Hansen Pharmaceutical Co Ltd (SZSE:002412) » Definitions » Piotroski F-Score

Hunan Hansen Pharmaceutical Co (SZSE:002412) Piotroski F-Score : 7 (As of Dec. 14, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Hunan Hansen Pharmaceutical Co Piotroski F-Score?

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Hunan Hansen Pharmaceutical Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Hunan Hansen Pharmaceutical Co's Piotroski F-Score or its related term are showing as below:

SZSE:002412' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 9
Current: 7

During the past 13 years, the highest Piotroski F-Score of Hunan Hansen Pharmaceutical Co was 9. The lowest was 3. And the median was 6.


Hunan Hansen Pharmaceutical Co Piotroski F-Score Historical Data

The historical data trend for Hunan Hansen Pharmaceutical Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hunan Hansen Pharmaceutical Co Piotroski F-Score Chart

Hunan Hansen Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 5.00 8.00 5.00 6.00

Hunan Hansen Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 6.00 7.00 7.00 7.00

Competitive Comparison of Hunan Hansen Pharmaceutical Co's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Hansen Pharmaceutical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hunan Hansen Pharmaceutical Co's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hunan Hansen Pharmaceutical Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Hunan Hansen Pharmaceutical Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Net Income was 95.273 + 58.265 + 42.229 + 30.259 = ¥226.0 Mil.
Cash Flow from Operations was 51.567 + 20.504 + 22.59 + 95.895 = ¥190.6 Mil.
Revenue was 271.389 + 254.033 + 226.413 + 213.536 = ¥965.4 Mil.
Gross Profit was 203.359 + 188.587 + 169.868 + 162.964 = ¥724.8 Mil.
Average Total Assets from the begining of this year (Sep23)
to the end of this year (Sep24) was
(2269.74 + 2336.489 + 2390.146 + 2453.231 + 2452.685) / 5 = ¥2380.4582 Mil.
Total Assets at the begining of this year (Sep23) was ¥2,269.7 Mil.
Long-Term Debt & Capital Lease Obligation was ¥0.0 Mil.
Total Current Assets was ¥1,040.1 Mil.
Total Current Liabilities was ¥325.5 Mil.
Net Income was 37.542 + 55.067 + 35.6 + 19.075 = ¥147.3 Mil.

Revenue was 234.912 + 250.178 + 221.494 + 212.469 = ¥919.1 Mil.
Gross Profit was 170.415 + 177.219 + 160.436 + 158.622 = ¥666.7 Mil.
Average Total Assets from the begining of last year (Sep22)
to the end of last year (Sep23) was
(2326.804 + 2290.944 + 2368.623 + 2278.678 + 2269.74) / 5 = ¥2306.9578 Mil.
Total Assets at the begining of last year (Sep22) was ¥2,326.8 Mil.
Long-Term Debt & Capital Lease Obligation was ¥0.0 Mil.
Total Current Assets was ¥830.3 Mil.
Total Current Liabilities was ¥388.0 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Hunan Hansen Pharmaceutical Co's current Net Income (TTM) was 226.0. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Hunan Hansen Pharmaceutical Co's current Cash Flow from Operations (TTM) was 190.6. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep23)
=226.026/2269.74
=0.09958233

ROA (Last Year)=Net Income/Total Assets (Sep22)
=147.284/2326.804
=0.06329884

Hunan Hansen Pharmaceutical Co's return on assets of this year was 0.09958233. Hunan Hansen Pharmaceutical Co's return on assets of last year was 0.06329884. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Hunan Hansen Pharmaceutical Co's current Net Income (TTM) was 226.0. Hunan Hansen Pharmaceutical Co's current Cash Flow from Operations (TTM) was 190.6. ==> 190.6 <= 226.0 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=0/2380.4582
=0

Gearing (Last Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=0/2306.9578
=0

Hunan Hansen Pharmaceutical Co's gearing of this year was 0. Hunan Hansen Pharmaceutical Co's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep24)=Total Current Assets/Total Current Liabilities
=1040.123/325.462
=3.19583546

Current Ratio (Last Year: Sep23)=Total Current Assets/Total Current Liabilities
=830.306/387.985
=2.14004665

Hunan Hansen Pharmaceutical Co's current ratio of this year was 3.19583546. Hunan Hansen Pharmaceutical Co's current ratio of last year was 2.14004665. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Hunan Hansen Pharmaceutical Co's number of shares in issue this year was 503.401. Hunan Hansen Pharmaceutical Co's number of shares in issue last year was 503.228. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=724.778/965.371
=0.75077664

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=666.692/919.053
=0.72541192

Hunan Hansen Pharmaceutical Co's gross margin of this year was 0.75077664. Hunan Hansen Pharmaceutical Co's gross margin of last year was 0.72541192. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep23)
=965.371/2269.74
=0.42532228

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep22)
=919.053/2326.804
=0.39498514

Hunan Hansen Pharmaceutical Co's asset turnover of this year was 0.42532228. Hunan Hansen Pharmaceutical Co's asset turnover of last year was 0.39498514. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+1+1+0+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Hunan Hansen Pharmaceutical Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Hunan Hansen Pharmaceutical Co  (SZSE:002412) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Hunan Hansen Pharmaceutical Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Hunan Hansen Pharmaceutical Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Hunan Hansen Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
Silver City Road, Long Ridge Industrial Park, Heshan District, Yiyang City, CHN, 413000
Hunan Hansen Pharmaceutical Co Ltd is producing Chinese and Western medicines. Its main dosage forms include large-volume injections, small-volume injections, oral liquids, tablets, hard capsules, granules, syrups, ointments, tinctures, and pills. The company's main products are Si Mo Tang Oral Liquid, Shuanquan Capsule, Ginkgo Biloba Capsule and Tianma Xingnao Capsule.
Executives
Luo Yong Qing Directors, executives
Liu Zheng Qing Directors, executives
Liu Ling An Director
Fu Jian Jun Executives
Liu Na Xin Independent director
Liu Hou Yao Directors, Directors, and Executives
He San Xing Directors, executives

Hunan Hansen Pharmaceutical Co Headlines

No Headlines